​

Benitec Biopharma Stock (NASDAQ:BNTC)

ForecastOwnershipFinancialsChart
Benitec Biopharma by TradingView

Previous Close

$15.92

52W Range

$5.74 - $17.15

50D Avg

$14.08

200D Avg

$11.79

Market Cap

$432.61M

Avg Vol (3M)

$50.16K

Beta

0.44

Div Yield

-

BNTC Company Profile

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

16

IPO Date

Jun 24, 2014

Website

BNTC Performance

BNTC Financial Summary

Jun 24Jun 23Jun 22
Revenue-$75.00K$73.00K
Operating Income$-22.49M$-19.08M$-17.85M
Net Income$-22.37M$-19.56M$-18.56M
EBITDA$-22.49M$-18.73M$-17.93M
Basic EPS$-0.01$-14.12$-38.62
Diluted EPS$-0.01$-14.12$-38.62

Fiscal year ends in Jun 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 18Jun 01, 18 | 5:00 PM

Peer Comparison

TickerCompany
NXTCNextCure, Inc.
ZVSAZyVersa Therapeutics, Inc.
CAPRCapricor Therapeutics, Inc.
APLMApollomics, Inc.
ALRNAileron Therapeutics, Inc.
BPTHBio-Path Holdings, Inc.
ZURAZura Bio Limited